Clinical characteristics according to mutation status of KIT and FLT3
| Clinical characteristic . | Mutation status . | P . | |||
|---|---|---|---|---|---|
| KIT and FLT3 mutated, n = 10 . | KIT mutated, n = 55 . | FLT3 mutated, n = 20 . | KIT/FLT3 wild type, n = 90 . | ||
| Median age, y (range) | 33 (19-50) | 42 (18-72) | 41 (19-74) | 42 (19-74) | .081 |
| Patients > 61 y, n (%) | 0 | 6 (11) | 2 (10) | 7 (8) | .76 |
| Male sex, n (%) | 8 (80) | 33 (60) | 9 (45) | 43 (48) | .14 |
| AML history, n (%) | .96 | ||||
| De novo | 10 (100) | 50 (91) | 19 (95) | 84 (93) | |
| Therapy-related | 0 | 5 (9) | 1 (5) | 6 (7) | |
| Median WBC count, × 109/L (range) | 86.3 (18.0-243.6) | 47.4 (1.2-271.0) | 43.4 (2.7-284.0) | 32.7 (1.1-294.9) | .033 |
| Missing data, n | 0 | 2 | 1 | 0 | |
| Median platelet count, × 109/L (range) | 34.5 (17-55) | 34 (7-529) | 37 (7-117) | 35 (8-380) | .92 |
| Missing data, n | 0 | 2 | 1 | 0 | |
| Median hemoglobin, g/dL (range) | 8.4 (2.5-12.3) | 9.3 (3-14.19) | 9 (5.5-12.69) | 9.2 (3.5-14.5) | .59 |
| Missing data, n | 0 | 2 | 1 | 0 | |
| Median % blood blasts (range) | 66 (44-94) | 55 (3-97) | 50 (7-90) | 35.5 (0-95) | .009 |
| Missing data, n | 0 | 4 | 1 | 4 | |
| Median % bone marrow blasts (range) | 80 (75-94) | 90 (80-99) | 90 (78.5-91) | 90 (78.5-99) | .72 |
| Missing data, n | 1 | 6 | 2 | 10 | |
| Extramedullary involvement, n (%) | .98 | ||||
| Present | 3 (30) | 16 (31) | 7 (35) | 30 (33) | |
| Absent | 7 (70) | 36 (69) | 13 (75) | 60 (67) | |
| Missing data | 0 | 3 | 0 | 0 | |
| Secondary chromosome aberrations, n (%) | |||||
| None | 5 (50) | 35 (66) | 13 (65) | 50 (59) | .72 |
| Trisomy 22 | 3 (30) | 6 (11) | 4 (20) | 18 (21) | .30 |
| Trisomy 8 | 2 (20) | 9 (17) | 2 (10) | 14 (17) | .88 |
| Other | 0 | 5 (9) | 1 (5) | 11 (13) | .65 |
| Missing data | 0 | 2 | 0 | 6 | |
| Clinical characteristic . | Mutation status . | P . | |||
|---|---|---|---|---|---|
| KIT and FLT3 mutated, n = 10 . | KIT mutated, n = 55 . | FLT3 mutated, n = 20 . | KIT/FLT3 wild type, n = 90 . | ||
| Median age, y (range) | 33 (19-50) | 42 (18-72) | 41 (19-74) | 42 (19-74) | .081 |
| Patients > 61 y, n (%) | 0 | 6 (11) | 2 (10) | 7 (8) | .76 |
| Male sex, n (%) | 8 (80) | 33 (60) | 9 (45) | 43 (48) | .14 |
| AML history, n (%) | .96 | ||||
| De novo | 10 (100) | 50 (91) | 19 (95) | 84 (93) | |
| Therapy-related | 0 | 5 (9) | 1 (5) | 6 (7) | |
| Median WBC count, × 109/L (range) | 86.3 (18.0-243.6) | 47.4 (1.2-271.0) | 43.4 (2.7-284.0) | 32.7 (1.1-294.9) | .033 |
| Missing data, n | 0 | 2 | 1 | 0 | |
| Median platelet count, × 109/L (range) | 34.5 (17-55) | 34 (7-529) | 37 (7-117) | 35 (8-380) | .92 |
| Missing data, n | 0 | 2 | 1 | 0 | |
| Median hemoglobin, g/dL (range) | 8.4 (2.5-12.3) | 9.3 (3-14.19) | 9 (5.5-12.69) | 9.2 (3.5-14.5) | .59 |
| Missing data, n | 0 | 2 | 1 | 0 | |
| Median % blood blasts (range) | 66 (44-94) | 55 (3-97) | 50 (7-90) | 35.5 (0-95) | .009 |
| Missing data, n | 0 | 4 | 1 | 4 | |
| Median % bone marrow blasts (range) | 80 (75-94) | 90 (80-99) | 90 (78.5-91) | 90 (78.5-99) | .72 |
| Missing data, n | 1 | 6 | 2 | 10 | |
| Extramedullary involvement, n (%) | .98 | ||||
| Present | 3 (30) | 16 (31) | 7 (35) | 30 (33) | |
| Absent | 7 (70) | 36 (69) | 13 (75) | 60 (67) | |
| Missing data | 0 | 3 | 0 | 0 | |
| Secondary chromosome aberrations, n (%) | |||||
| None | 5 (50) | 35 (66) | 13 (65) | 50 (59) | .72 |
| Trisomy 22 | 3 (30) | 6 (11) | 4 (20) | 18 (21) | .30 |
| Trisomy 8 | 2 (20) | 9 (17) | 2 (10) | 14 (17) | .88 |
| Other | 0 | 5 (9) | 1 (5) | 11 (13) | .65 |
| Missing data | 0 | 2 | 0 | 6 | |